Rigel Pharmaceuticals | RIGL - Current Assets


Rigel Pharmaceuticals reported $214.93M in Current Assets for its fiscal quarter ending in September of 2025.





Current Assets Change Date
Agenus USD 78.81M 16.47M Jun/2026
Amgen USD 34.96B 3.49B Jun/2026
Anika Therapeutics USD 99.19M 5.63M Jun/2026
Arrowhead Research USD 1.67B 168.34M Jun/2026
AstraZeneca USD 27.97B 1.65B Jun/2026
BioMarin Pharmaceutical USD 3.97B 633.45M Jun/2026
Bristol-Myers Squibb USD 29.77B 1.19B Sep/2026
Celldex Therapeutics USD 724.93M 265.71M Jun/2026
Daiichi Sankyo JPY 2.23T 91.92B Jun/2026
Eli Lilly USD 65.26B 591M Sep/2026
Halozyme Therapeutics USD 933.02M 70.01M Jun/2026
Heron Therapeutics USD 229.84M 861K Jun/2026
Intrexon USD 23.72M 45.04M Jun/2024
Ionis Pharmaceuticals USD 2.49B 446.73M Jun/2026
Karyopharm Therapeutics USD 126.33M 23.19M Mar/2026
Ligand Pharmaceuticals USD 1.46B 591.7M Jun/2026
MacroGenics USD 321.69M 139.16M Jun/2026
Neurocrine Biosciences USD 1.64B 798.6M Jun/2026
Pfizer USD 41.36B 1.46B Jun/2026
Regeneron Pharmaceuticals USD 20.8B 2.35B Sep/2026
Rigel Pharmaceuticals USD 214.93M 39.53M Sep/2025
Sangamo BioSciences USD 49.89M 12.3M Jun/2025
Ultragenyx Pharmaceutical USD 606M 51M Jun/2026
Veracyte USD 574.78M 52.6M Jun/2026